InvestorsHub Logo
Followers 6
Posts 121
Boards Moderated 0
Alias Born 09/05/2023

Re: None

Tuesday, 09/19/2023 7:05:10 AM

Tuesday, September 19, 2023 7:05:10 AM

Post# of 463021
Even if you are skeptical about Alzheimer's for Blarcamesine, Rhett syndrome rare disease approval is highly likely and will move the stock to at least $10. Easy double within 3 months, and likely much more.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News